Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim versus filgrastim in children under 6 years with rhabdomyosarcoma or Wilms tumour receiving myelosuppressive chemotherapy
2021-004792-14Phase 3
- Sponsor
- Intas Pharmaceuticals
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chemotherapy-induced neutropenia (CIN) comparing Pegfilgrastim arm with Filgrastim active control arm (2 arms). Primary endpoint: Efficacy of pegfilgrastim versus filgrastim.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2021-004792-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004792-14.